ESR1 and breast cancer: A proof of liquid biopsy’s usefulness in the management of BC patients is the detection of ESR1 mutations in ctDNA obtained from plasma of ER-positive metastatic BC patients, a biomarker of aromatase inhibitor therapy resistance [85].